And it got me thinking: why do lab supply firms get to have all the fun?

You’ve got Roche AG’s diagnostic division using a Motley-Poison-Whitesnake style rock anthem and power ballad to promote its xCELLigence cellular analysis system. And there’s Bio-Rad Laboratories Inc., the forefathers of funniness, with their “We Are the World” tribute to PCR and my personal favorite, the Village People spoof “GTCA.”

But who’s representin’ for biotech? Please post in the comments if you know of any funny biotech videos. The closest thing I could find was this promo about the troubles with existing glaucoma regimens. And it wasn’t from Genentech Inc. or Allergan Inc. It was a promo for Lumenis Selective Laser Trabeculoplasty.

The issue may have less to do with the lack of social media guidance for drug-makers and more to do with reaching your target audience. (See BioWorld Today, July 20, 2011.)

According to Richard Milne, digital marketing director at Life Technologies Corp., lab supply firms are selling largely into academic and government research environments, and there are “lots of relatively early scientists in these businesses.” Younger scientists tend to be more receptive to this type of outreach, as evidenced by the videos they create themselves (check out this Lady Gaga remake from Baylor College of Medicine).

[Note: Life Tech has some pretty funny videos, too. Our favorites are the LEGO animation build-it rap and 007-style short “Live and Let Amplify.”]

There’s also the fact that most biotechs are focused on treating debilitating diseases, which can make the integration of comedy into a marketing campaign difficult. But who knows – maybe as the older demographic becomes more tech savvy, we’ll see some of the biotechs who are already active in the world of apps crank out some videos.

To view all of these videos AND MORE of BioWorld’s favorites, check out the “Best Singing Scientists” playlist on our YouTube channel.

Check out our interview with Nigel Gaymond, the chief executive of the UK’s BioIndustry Association, in which he lays out the state of the UK biotech sector.

We also chatted with Keith A. Katkin, president and CEO of Avanir Pharmaceuticals about his company’s newly approved drug Nuedexta, the first and only FDA-approved treatment for pseudobulbar affect.

BIO’s President and CEO, James C. Greenwood, shared BIO’s legislative goals.

We also posted video of BioWorld’s session, Starting up Biotechs in the New Normal World, featuring a lively discussion about the post-2008 world of venture financing by panelists Stuart Collinson, CEO of Tioga Pharmaceuticals Inc.; Walter Ogier, president and CEO of Acetylon Pharmaceuticals Inc.; Art Pappas, managing partner of Pappas Ventures; and Edward Tenthoff, senior research analyst with Piper Jaffray Ventures.

But that’s just a handful of our video offerings. We stopped dozens of conference attendees in the hallways to get their thoughts on the #BIO2011 experience. Check out the full playlist to relive the misty watercolor conference memories (sorry!).